Arvinas heads into its June 24 earnings with the stock down 24% over the past month and defensive positioning in the options market at its most extreme level of the year.
The clearest tension this week is between what analysts think the stock is worth and where the market has taken it. Seven buy-rated analysts have an average target well above $18 — Barclays raised its target to $20 in mid-May, Citi lifted to $24 in early May — yet the stock closed Tuesday at $8. That gap has widened sharply. The stock fell nearly 7% on Tuesday alone and is off more than 10% for the week, leaving it roughly 55% below the analyst consensus. The Street's conviction, in other words, is running directly against the price action.
Options traders are leaning defensive at the most pronounced level in a year. The put/call ratio jumped to 0.296 on June 2 — a new 52-week high, and more than three standard deviations above its 20-day average of 0.211. That is an unusual spike in downside demand for a name where call volume typically dominates. Whether this reflects hedging ahead of the June 24 report or genuine directional bets against the stock, the options market is sending its most cautious signal since at least last June.
Short interest is building, though it tells a somewhat more measured story. At roughly 7.9% of the free float — or closer to 9.1% using the ORTEX estimate — the short position has grown about 8% over the past week and 17% over the past month. That is a real and accelerating increase. The borrow market, however, remains completely unconstricted. Availability runs at more than 4,600% of short interest, meaning there are roughly 47 million shares available to borrow against a short position of around 5 million. Cost to borrow ticked up 17% this week but remains negligible at 0.5% annualised. New shorts face no friction whatsoever in establishing positions. The ORTEX short score has crossed back above 50, sitting at 50.5, after climbing from the mid-48s in late May — a modest but directional move.
Insider activity adds a complicating layer. On May 11, five executives — CEO Randy Teel, CFO Andrew Saik, CMO Noah Berkowitz, Chief Accounting Officer David Loomis, and Chief Scientific Officer Angela Cacace — all sold shares at prices around $9.94. The sales were modest in dollar terms: none exceeded $115,000. They were broadly interpreted as routine, given the uniform timing and small size. But the stock has since fallen further, and the cluster of C-suite selling at a price the market has now moved well below is worth noting heading into earnings. The one meaningful counter-signal came from Lead Independent Director Briggs Morrison, who bought 20,000 shares at $13.40 in early March — a purchase that is now deeply underwater but one that represents the only notable insider buy in the recent record.
Heading into June 24, the most recent earnings history is instructive without being predictive. The May 2026 Q1 release produced a modest 2% next-day gain but then gave back 11.5% over the following five days. A separate data point from May 11 shows a 5.3% one-day drop with a 13.2% five-day loss. The pattern — a small initial move followed by sustained selling — has been the dominant template. With the stock already deep in drawdown territory and options pricing at their most defensive of the year, the upcoming print is less about whether Arvinas can deliver on ARV-102's Parkinson's programme and more about whether management can frame a credible path to closing the gap between analyst conviction and market reality.
See the live data behind this article on ORTEX.
Open ARVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
